Trans Activator Of Transcription (Tat) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Trans Activator Of Transcription (Tat) – Pipeline Review, H2 2016’, provides in depth analysis on Trans Activator Of Transcription (Tat) targeted pipeline therapeutics.

The report provides comprehensive information on the Trans Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Trans Activator Of Transcription (Tat)

The report reviews Trans Activator Of Transcription (Tat) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics and enlists all their major and minor projects

The report assesses Trans Activator Of Transcription (Tat) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Trans Activator Of Transcription (Tat) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Trans Activator Of Transcription (Tat)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Trans Activator Of Transcription (Tat) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Akshaya Bio Inc

Biosantech SA

Cannabis Science Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Trans Activator Of Transcription (Tat) Overview 6

Therapeutics Development 7

Trans Activator Of Transcription (Tat) - Products under Development by Stage of Development 7

Trans Activator Of Transcription (Tat) - Products under Development by Therapy Area 8

Trans Activator Of Transcription (Tat) - Products under Development by Indication 9

Trans Activator Of Transcription (Tat) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Trans Activator Of Transcription (Tat) - Products under Development by Companies 12

Trans Activator Of Transcription (Tat) - Products under Development by Universities/Institutes 14

Trans Activator Of Transcription (Tat) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Trans Activator Of Transcription (Tat) - Companies Involved in Therapeutics Development 22

Akshaya Bio Inc 22

Biosantech SA 23

Cannabis Science Inc 24

Trans Activator Of Transcription (Tat) - Drug Profiles 25

CSTATI-1 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

HIV vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

HIV vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

HIV vaccine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HIV-1 vaccine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Recombinant Protein to Inhibit Tat and Rev for HIV-1 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Trans Activator Of Transcription (Tat) - Dormant Projects 34

Trans Activator Of Transcription (Tat) - Discontinued Products 35

Trans Activator Of Transcription (Tat) - Featured News & Press Releases 36

Jun 08, 2016: Improving the Effect of HIV Drugs by Use of the Tat Vaccine 36

Mar 15, 2016: Publication in Retrovirology of the results of Biosantech's phase IIA clinical trial for the anti-HIV candidate vaccine 37

Jul 29, 2015: Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV and Kaposi Sarcoma Drug Development Program 37

Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests 38

Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I 39

Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma 40

Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 41

Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1 42

Appendix 43

Methodology 43

Coverage 43

Secondary Research 43

Primary Research 43

Expert Panel Validation 43

Contact Us 43

Disclaimer 44

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Akshaya Bio Inc, H2 2016 22

Pipeline by Biosantech SA, H2 2016 23

Pipeline by Cannabis Science Inc, H2 2016 24

Dormant Projects, H2 2016 34

Discontinued Products, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports